Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.
In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.
Intensifying competition, pricing pressure and copycat versions of its weight-loss drugs are holding back sales at the pharma ...
This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...
Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...
Opinion
16hOpinion
Don’t let copycat GLP-1 weight loss drugs exploit Pa.'s most vulnerable people | Opinion
Unregulated compounded GLP-1s are not the same as the legitimate medications that doctors prescribe for weight loss and chronic disease management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback